Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TYSABRI pregnancy exposure registry

Trial Profile

TYSABRI pregnancy exposure registry

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TPER; TYGRIS
  • Sponsors Biogen Idec
  • Most Recent Events

    • 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Oct 2010 Preliminary results were presented in an abstarct at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2010 According to an abstract of preliminary results, presented at the 26th Congress of ECTRIMS, as of 23 February 2010, 198 patients were registered prospectively to TPER, with 148 outcomes reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top